-
公开(公告)号：US4372890A
公开(公告)日：1983-02-08
申请号：US265838
申请日：1981-05-21
CPC分类号： C07F15/0093
摘要： The present invention relates to a platinum compound having the formula ##STR1## wherein R represents hydrogen atom, an alkali metal atom or a lower alkyl group. The platinum compound is effective as an antitumor and antimicrobial drug.
摘要翻译： 本发明涉及具有式（1）的铂化合物，其中R表示氢原子，碱金属原子或低级烷基。 铂化合物作为抗肿瘤和抗菌药物是有效的。
-
公开(公告)号：US4504487A
公开(公告)日：1985-03-12
申请号：US431374
申请日：1982-09-30
CPC分类号： C07F15/0093
摘要： The present invention relates to a platinum compound having the formula ##STR1## wherein R represents hydrogen atom, an alkali metal atom or a lower alkyl group. The platinum compound is effective as an antitumor and antimicrobial drug.
-
3.发明授权Method for inhibiting the formation of urinary calculus utilizing 24,25-(OH).sub.2 -D.sub.3 失效利用24,25-（OH）2-D3抑制尿结石形成的方法
公开(公告)号：US4866047A
公开(公告)日：1989-09-12
申请号：US103788
申请日：1987-10-01
申请人： Hideyuki Yamato , Yuji Maeda , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Fumio Hirose , Tadaaki Kato , Chikao Yoshikumi
发明人： Hideyuki Yamato , Yuji Maeda , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Fumio Hirose , Tadaaki Kato , Chikao Yoshikumi
CPC分类号： A61K31/59 , Y10S514/891
摘要： Disclosed herein is a method for inhibiting the formation of urinary calculus by the administration of 24,25-dihydroxycholecarciferol.
摘要翻译： 本文公开了通过施用24,25-二羟基胆碱酯抑制尿结石形成的方法。
-
4.发明授权Antinephritic pharmaceutical composition containing 24, 25-dihydroxycholecalciferol as an active ingredient 失效含有25,25-二羟基胆钙化甾醇作为活性成分的抗肾上腺药物组合物
公开(公告)号：US4628050A
公开(公告)日：1986-12-09
申请号：US800114
申请日：1985-11-20
申请人： Yuji Maeda , Hideyuki Yamato , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
发明人： Yuji Maeda , Hideyuki Yamato , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
CPC分类号： A61K31/59
摘要： Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating nephritic disease of a compound of 24,25-dihydroxycholecalciferol as an active ingredient and a pharmaceutically acceptable carrier.
摘要翻译： 本文公开了以剂量单位形式的药物组合物，其包含有效治疗24,25-二羟基胆钙化甾醇化合物作为活性成分的肾炎疾病的剂量和药学上可接受的载体。
-
5.发明授权Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient 失效含有24,25-二羟基胆钙化甾醇作为活性成分的抗骨质疏松药物组合物
公开(公告)号：US4590184A
公开(公告)日：1986-05-20
申请号：US662044
申请日：1984-10-18
申请人： Yuji Maeda , Hideyuki Yamato , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
发明人： Yuji Maeda , Hideyuki Yamato , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
CPC分类号： A61K31/59
摘要： Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating osteoporosis of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutically acceptable carrier.
摘要翻译： 本文公开了一种剂量单位形式的药物组合物，其包含有效治疗24,25-二羟基胆钙化甾醇和药学上可接受的载体的化合物的骨质疏松症的剂量。
-
6.发明授权Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia 失效将24,25-二羟基胆钙化醇给予患有高钙血症的人的方法
公开(公告)号：US4442093A
公开(公告)日：1984-04-10
申请号：US374702
申请日：1982-05-04
申请人： Yuji Maeda , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
发明人： Yuji Maeda , Takayoshi Fujii , Yasuhiko Kobayashi , Kenichi Saito , Tadaaki Kato , Chikao Yoshikumi
IPC分类号： A61K31/59
CPC分类号： A61K31/59 , Y10S514/866 , Y10S514/885 , Y10S514/908 , Y10S514/926 , Y10S514/927
摘要： Pharmaceutical composition in dosage unit form, comprising a therapeutically effective amount of 24,25-dihydroxycholecalciferol and a pharmaceutically acceptable carrier. The compound of 24,25-dihydroxycholecalciferol has anti-hypercalcemic activity, anti-ulcer activity, activity of preventing reduction of immunity, activity of controlling magnesium-metabolism, anti-hyperphosphatemic activity, activity of controlling blood sugar level and anti-tumor activity.
摘要翻译： 药物组合物，其剂量单位形式包括治疗有效量的24,25-二羟基胆钙化甾醇和药学上可接受的载体。 24,25-二羟基胆钙化甾醇的化合物具有抗高钙血症活性，抗溃疡活性，防止免疫力降低的活性，控制镁代谢活性，抗高磷血症活性，控制血糖水平和抗肿瘤活性的活性。
-
7.发明授权Phenylalanine-glycine derivatives, process for preparation thereof, and pharmaceutical composition containing said derivatives 失效苯丙氨酸 - 甘氨酸衍生物，其制备方法和含有所述衍生物的药物组合物
公开(公告)号：US5470960A
公开(公告)日：1995-11-28
申请号：US371564
申请日：1995-01-11
申请人： Koichi Niimura , Takako Kawabe , Takao Ando , Kenichi Saito
发明人： Koichi Niimura , Takako Kawabe , Takao Ando , Kenichi Saito
IPC分类号： A61K38/00 , A61P35/00 , C07C271/18 , C07C271/22 , C07K1/02 , C07K1/06 , C07K1/113 , C07K5/06 , C07K5/065 , C07H15/24 , C07C229/00
CPC分类号： C07K5/06078 , C07C271/22 , A61K38/00
摘要： A phenylalanine-glycine derivative of the general formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described.The novel conjugate of the phenylalanine-glycine derivative and the antitumor substance exhibits superior antitumor activity in comparison with the case wherein an antitumor substance is administered singly or as a mixture with phenylalanine.
摘要翻译： 通式（I）的苯丙氨酸 - 甘氨酸衍生物：其中R表示抗肿瘤物质的残基或其盐或酯，其制备方法和含有它们的药物组合物为 描述。 苯丙氨酸 - 甘氨酸衍生物与抗肿瘤物质的新结合物与单独给予抗肿瘤物质或与苯丙氨酸的混合物相比，具有优异的抗肿瘤活性。
-
8.发明授权Phenylalanine-glycine compounds having anti-tumor activity, process for preparation thereof, and pharmaceutical composition containing said compounds 失效具有抗肿瘤活性的苯丙氨酸 - 甘氨酸化合物，其制备方法和含有所述化合物的药物组合物
公开(公告)号：US5411964A
公开(公告)日：1995-05-02
申请号：US31478
申请日：1993-03-15
申请人： Koichi Niimura , Takako Kawabe , Takao Ando , Kenichi Saito
发明人： Koichi Niimura , Takako Kawabe , Takao Ando , Kenichi Saito
IPC分类号： A61K38/00 , A61P35/00 , C07C271/18 , C07C271/22 , C07K1/02 , C07K1/06 , C07K1/113 , C07K5/06 , C07K5/065 , A61K31/505 , A61K31/215 , C07C229/28 , C07D239/12
CPC分类号： C07K5/06078 , C07C271/22 , A61K38/00
摘要： A phenylalanine-glycine compound of formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described. The novel conjugate of the phenylalanine-glycine compound and the antitumor substance exhibits superior antitumor activity in comparison with the case wherein an antitumor substance is administered alone or as a mixture with phenylalanine.
摘要翻译： 描述了式（I）的苯丙氨酸 - 甘氨酸化合物：抗肿瘤物质或其盐或酯，其制备方法和含有该物质的药物组合物。 苯丙氨酸 - 甘氨酸化合物和抗肿瘤物质的新结合物与其中单独给予抗肿瘤物质或与苯丙氨酸的混合物的情况相比表现出优异的抗肿瘤活性。
-
公开(公告)号：US4975422A
公开(公告)日：1990-12-04
申请号：US368232
申请日：1989-06-19
CPC分类号： C07K14/375 , A61K38/00
摘要： The present invention discloses an angiogenesis inhibitor containing as an active ingredient protein-polysaccharides produced by extraction of mycelia or fruit bodies obtained from culture of a Basidiomycete belonging to a genus Coriolus.The protein-polysaccharide contains about 18 to about 38% by weight of protein, being free from protein-polysaccharides having molecular weight of less than 5,000.More in detail, said protein-polysaccharides of the present invention contain 3 to 6% of nitrogen, a polysaccharide portion thereof, as the main fraction, is composed of .beta.-D-glucan and this glucan portion has branched structures containing 1.fwdarw.3, 1.fwdarw.4 and 1.fwdarw.6 bonds, wherein the protein-component amino acids are mostly acidic amino acids of aspartic acid and glutamic acid, and neutral amino acids of valine and leucine, while the basic amino acids of lysine and alginine are small in content, and the protein-polysaccharide is soluble in water but hardly soluble in methanol, pyridine, chloroform, benzene and hexane and starts to be gradually decomposed at about 120.degree. C.
-
公开(公告)号：US09617960B2
公开(公告)日：2017-04-11
申请号：US13988858
申请日：2011-12-07
申请人： Kenichi Saito
发明人： Kenichi Saito
CPC分类号： F02M51/00 , F02D41/3094 , F02D41/3854 , F02D2200/0602 , F02D2250/02
摘要： A fuel supply apparatus for an internal combustion engine includes: a feed pump capable of feeding a fuel of the internal combustion engine; a high pressure fuel pump that pressurizes the fuel fed from the feed pump; and a second injector that supplies the pressurized high-pressure fuel to the internal combustion engine selectively. An ECU of the fuel supply apparatus includes: a pulsation width detection unit that detects a pulsation width in a pressure of the fuel fed from the feed pump to the high pressure fuel pump; and a feeding condition determination unit that determines that a condition variation causing fuel vapor to form in the fuel fed to the high pressure fuel pump has occurred when the pulsation width detected by the pulsation width detection unit falls rapidly to a preset threshold variation width.
-
-
-
-
-
-
-
-
-
搜索结果
156 条记录 (耗时 0.024 秒)
